Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Losartan prevents thromboxane A2/prostanoid (TP) receptor mediated increase in microvascular permeability in the rat.

Valentin JP, Jover B, Maffre M, Bertolino F, Bessac AM, John GW.

Am J Hypertens. 1997 Sep;10(9 Pt 1):1058-63.

PMID:
9324114
2.

[Critical review of the various treatments of temporomandibular joint pain-dysfunction syndrome. What will be the psychosomatic approach to these patients?].

Fleury JE, Deboets D, Maffre M, Assaad C, Ferrey G.

Rev Stomatol Chir Maxillofac. 1997 Jan;98(1):50-4. Review. French.

PMID:
9273678
3.

Nitric oxide regulation of TP receptor-mediated pulmonary vasoconstriction in the anesthetized, open-chest rat.

Valentin JP, Bessac AM, Maffre M, John GW.

Eur J Pharmacol. 1996 Dec 19;317(2-3):335-42.

PMID:
8997619
4.

Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.

Bertolino F, Valentin JP, Maffre M, Grelac F, Bessac AM, Maclouf J, Delhon A, Lévy-Toledano S, Patoiseau JF, Colpaert FC, et al.

Br J Pharmacol. 1995 May;115(1):210-6.

5.

TxA2 receptor activation elicits organ-specific increases in microvascular permeability in the rat.

Bertolino F, Valentin JP, Maffre M, Bessac AM, John GW.

Am J Physiol. 1995 Feb;268(2 Pt 2):R366-74.

PMID:
7864230
6.

[Losartan prevents pulmonary hypertension induced by a thromboxane A2 analog].

Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW.

Arch Mal Coeur Vaiss. 1994 Aug;87(8):971-4. French.

PMID:
7755474
7.

Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist.

Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW.

J Pharmacol Exp Ther. 1994 Feb;268(2):747-52.

PMID:
8113986

Supplemental Content

Loading ...
Support Center